{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:20:58Z","timestamp":1791580858116,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82101364"],"award-info":[{"award-number":["82101364"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82322023"],"award-info":[{"award-number":["82322023"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jneuroim.2024.578285","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T12:08:03Z","timestamp":1704715683000},"page":"578285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"387","author":[{"given":"Chengyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuetao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangshu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Cai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaibin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2024.578285_bb0005","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121804119","article-title":"Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders","volume":"119","author":"Damato","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0010","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/rheumatology\/kev036","article-title":"Longer duration of B cell depletion is associated with better outcome","volume":"54","author":"Dias","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jneuroim.2024.578285_bb0015","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s00415-022-11048-4","article-title":"Individualized regimen of low-dose rituximab monotherapy for new-onset AChR-positive generalized myasthenia gravis","volume":"269","author":"Du","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.971366","article-title":"Low dose versus standard dose rituximab for the treatment of antiphospholipid syndrome: a pilot study from a tertiary medical center","volume":"13","author":"Gan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0025","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0030","first-page":"8","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2","author":"Graf","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.939062","article-title":"Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody","volume":"13","author":"Hou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0040","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1093\/rheumatology\/keac438","article-title":"Low dose rituximab is efficacious in refractory idiopathic inflammatory myopathies","volume":"62","author":"Janardana","year":"2022","journal-title":"Rheumatol. (Oxford, England)"},{"key":"10.1016\/j.jneuroim.2024.578285_bb0045","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-rituximab antibody in patients with NMOSDs treated with low dose rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577790","article-title":"Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis","volume":"363","author":"Ma","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2015.03.016","article-title":"The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy","volume":"282","author":"Quan","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0065","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0070","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(19)30066-9","article-title":"Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial","volume":"1","author":"Verhoef","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104127","article-title":"Different doses of rituximab for the therapy of neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"68","author":"Wei","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0090","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3389\/fneur.2020.00642","article-title":"Retrospective observation of low-dose rituximab treatment in Chinese patients with neuromyelitis optica spectrum disorders in a real-world setting","volume":"11","author":"Xiao","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0095","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2024.578285_bb0100","first-page":"8","article-title":"B-cell compartmental features and molecular basis for therapy in autoimmune disease","author":"Zhang","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:43:33Z","timestamp":1759049013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572824000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":20,"alternative-id":["S0165572824000031"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578285","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"578285"}}